Unlocking New Cures: How Functional Genomic Screening Revolutionizes Drug Discovery
![A logo for the brand Revvity](https://assets.technologynetworks.com/production/dynamic/images/vendor/253/221-revvity-480x270.jpg)
In this exclusive Teach Me in 10 episode, Dr. James Goldmeyer, Associate Director at Revvity, explores the transformative impact of functional genomic screening in drug discovery. Revvity, a leading organization, offers comprehensive solutions across research, development, diagnosis, and treatment. Dr. Goldmeyer discusses how this cutting-edge technique, involving CRISPR-based technologies and RNA interference, enhances precision in developing personalized treatments and bridges the gap left by traditional methods.
The discussion highlights functional genomic screening's pivotal role in drug discovery, aiding in target identification, drug response mechanisms, and in vivo tumor biology. It also addresses potential disadvantages, providing a well-rounded understanding.
Emphasizing Revvity's focus on gene modification and its potential applications in various diseases, the interview reveals how functional genomic screening accelerates drug discovery and supports innovative cell-based therapies.
Further Resources:
- To learn more about functional genomic screening and its applications in cell- based therapies, you can watch this informative video by Dr. James Goldmeyer on Revvity's website
- Functional Genomic Screening in Drug Discovery: infographic
- Leveraging multiplatform cell-based screening for target ID: on demand webinar
- Learn more about how CRISPR-based functional genomics is transforming discovery and how it enables researchers to explore further, becoming a key tool in pre-clinical drug discovery: whitepaper
- CRISPR-Cas9 is a powerful approach to advance drug discovery research. Learn more about the various screening options and considerations to help you select the right screening approach suited to the need: App Note
- Combining different tools like High-Content Phenotypic screening into an advanced strategy: see whitepaper